CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The strong pharmaceutical product pipeline
4.1.2. Rising government funding for pharmaceutical & biotechnology industries
4.1.3. The innovation of novel drugs and rise in R&D activities
4.1.4. Increased emphasis on quality assurance and quality control in industries
4.1.5. High incidence and large economic burden of chronic diseases
4.2. Market Restraints & Challenges
4.2.1. High degree of consolidation act
4.2.2. Lengthy approval procedures and strict regulatory frameworks
4.3. Market Opportunities
4.3.1. Growing pharmaceutical outsourcing and emerging countries
CHAPTER 5. GLOBAL VIRAL CLEARANCE MARKET– BY METHOD
5.1. Viral Detection Method
5.1.1. Plaque Assays
5.1.2. PCR (Polymerase Chain Reaction)
5.1.3. Elisa
5.1.4. Others
5.2. Viral Removal
5.2.1. Chromatography
5.2.2. Nanofiltration
5.2.3. Precipitation
5.2. Viral Inactivation
5.2.1. Solvent Detergent Method
5.2.2. Pasteurization
5.2.3. Others
CHAPTER 6. GLOBAL VIRAL CLEARANCE MARKET – BY APPLICATION
6.1. Vaccines and Therapeutics
6.2. Blood and Blood Products
6.3. Cellular and Gene Therapy Products
6.4. Tissue and Tissue Products
6.5. Stem Cell Products
CHAPTER 7. GLOBAL VIRAL CLEARANCE MARKET – BY END USER
7.1. Biopharmaceutical & Biotechnology Companies
7.2. Research Laboratories and Institutes
7.3. CROs
7.4. Others
CHAPTER 8. GLOBAL VIRAL CLEARANCE MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL VIRAL CLEARANCE MARKET - COMPANY PROFILES
9.1. Lonza Group
9.2. SGS S.A.
9.3. Sigma-Aldrich Corporation
9.4. Charles River Laboratories International, Inc.
9.5. BSL Bioservice
9.6. Merck KGaA
9.7. Avance Biosciences Inc.
9.8. Texcell, Inc.
9.9. Clean Cells, Inc.
9.10. Wuxi Pharmatech (CAYMAN) Inc.
9.11. F- Hoffmann-La Roche Ltd
9.12. Pfizer, Inc.
9.13. Illumina, Inc.
9.14. Promocell GmbH
9.15. Eppendorf AG
CHAPTER 10. GLOBAL VIRAL CLEARANCE MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
